Lung cancer

Researchers are testing whether adding vorinostat to standard vinorelbine is safe and tolerable in adults with advanced solid tumors. The trial enrolls about 30 people and escalates the vorinostat dose in small groups to find the highest dose patients can take without severe side…

Researchers are testing whether adding niraparib to osimertinib is safe and tolerable for people with EGFR-mutated advanced lung cancer that has progressed on osimertinib. The Phase 1 trial enrolls about 20 participants who receive both drugs. The main goal is to find the highest…

This trial tests a new drug called acasunlimab, either alone or combined with the cancer drug pembrolizumab, in people with advanced non-small cell lung cancer that has come back or stopped responding to standard treatments. About 125 adults will receive the drugs intravenously e…

Researchers are testing an experimental oral drug called RVU120 in adults with advanced or metastatic solid tumors that have worsened after standard treatments. The trial has two parts: first, they check safety and find the best dose; second, they measure how well the drug shrink…

This study tested a combination of an immunotherapy drug (nivolumab) and low-dose chemotherapy in children and teenagers whose solid tumors had not responded to standard treatments. The goal was to see if the combination was safe and could help control the cancer. The trial was s…

This phase 3 trial tests whether adding vibostolimab to pembrolizumab (Keytruda) helps people with PD-L1 positive metastatic non-small cell lung cancer live longer than pembrolizumab alone. Over 1,200 participants received either the combination or pembrolizumab every three weeks…

This phase 3 trial tested a new immunotherapy combination (pembrolizumab plus vibostolimab) with chemotherapy against the standard pembrolizumab-plus-chemotherapy for people with advanced non-small cell lung cancer. The study enrolled 739 participants who had not received prior t…

Researchers are testing an experimental daily capsule called AP-L1898 in adults with locally advanced or metastatic non-small cell lung cancer that cannot be treated with chemoradiotherapy. The study enrolls people whose cancer has worsened after standard treatment and whose tumo…

This early-stage trial tested a new antibody drug called GEN1057 in 23 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see how the drug behaves in the body. The study was terminated early, so results ar…

This trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…

This early-stage trial tests whether combining two drugs, INCB099280 and adagrasib, is safe and tolerable for adults with advanced solid tumors that carry a specific genetic change called KRAS G12C. The study enrolls people whose cancer has spread or is locally advanced and who h…

This phase III trial tests whether adding denosumab, a drug often used for bone health, to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. About 595 adults with advanced disease will receive either chemotherapy alone or chemotherapy plus d…

This early-phase study tested an investigational drug called MGY825 in 41 adults with advanced non-small cell lung cancer that has specific genetic changes (NFE2L2/KEAP1/CUL3 mutations). The main goal was to check the drug's safety and find the right dose. The study was terminate…

This study tests whether a daily kava drink can help active smokers who don't plan to quit reduce their smoking and lower their risk of lung cancer. Twenty adult smokers will take kava daily for several months. Researchers will check how well participants stick with the regimen, …

This early-stage trial tests an experimental cell therapy called GAIA-102 in people with advanced or relapsed non-small cell lung cancer. Researchers give GAIA-102 alone or with the immunotherapy drug pembrolizumab to see if the combination is safe and can shrink tumors. The stud…

This early-phase study tests an experimental drug called INCB177054, given alone or with another drug (retifanlimab), in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Abo…

This study looked at whether switching from the immunotherapy durvalumab to the targeted drug sotorasib can better control locally advanced non-small cell lung cancer in patients with a KRAS G12C mutation and signs of remaining cancer (minimal residual disease). Ten participants …

This early-phase trial tests a personalized cell therapy called TCR-T cells, engineered to recognize and attack cancer cells with a specific KRAS mutation. Up to 18 adults with advanced pancreatic cancer who have exhausted standard treatments will receive a single infusion of the…

This early-stage study tested a new drug called BI 765049, alone or combined with another drug (ezabenlimab), in 21 Asian adults with advanced solid tumors (stomach, colorectal, pancreatic, liver, head and neck, or lung cancer) that have a specific marker called B7-H6. The main g…

This early-phase trial tested ASP1012, a virus engineered to infect and kill cancer cells while making them visible to the immune system. It was given alone or with the immunotherapy pembrolizumab to 15 adults with advanced solid tumors. The main goals were to check safety and fi…

This study tests whether specially engineered immune cells (EIE) can safely fight cancer. Researchers take a patient's own immune cells, modify them to target tumor-related markers, and infuse them back. The trial involves 100 people with various cancers whose tumors show specifi…

This early-phase trial tested a combination of two oral drugs, mirdametinib and brimarafenib, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. Th…

This early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…

This phase II trial is testing whether bortezomib, a drug that interferes with cancer cell growth, can help people with advanced non-small cell lung cancer. Participants have stage IIIB or IV disease and have not received prior chemotherapy. The main goal is to see if the drug ca…

This trial tested an experimental drug called ASP1570 in adults with advanced solid tumors that had spread or could not be removed by surgery. The drug aims to help the body's immune T-cells attack tumors that have become resistant. The study was in two parts: first to find a saf…

This trial is testing whether an experimental drug called NC410, when combined with the immunotherapy drug pembrolizumab, can safely and effectively treat people with advanced solid tumors that have not responded to standard immunotherapy or that are unlikely to respond. The stud…

This trial investigates a combination of two drugs: EP0057, a chemotherapy drug wrapped in a nanoparticle to help it reach cancer cells, and olaparib, which stops cancer cells from fixing DNA damage. The study includes adults with small cell lung cancer, bladder cancer, or prosta…

This early-phase trial tested a new antibody drug, GEN1055, in 21 adults with advanced solid tumors. The goal was to check safety and find the right dose when used alone or with pembrolizumab (with or without chemotherapy). The study was stopped early, but results help guide futu…

This early-phase trial tests whether an experimental protein called CD24Fc can help people with advanced solid tumors recover from severe immune-related side effects caused by immunotherapy. These side effects occur when the immune system attacks healthy tissues. CD24Fc is design…

This phase 2 trial aimed to see if infliximab and intravenous immunoglobulin (IVIG) could help cancer patients with severe lung inflammation that didn't respond to steroids. Only one patient was enrolled before the study was terminated, so no meaningful results were obtained. The…

This early-stage trial is testing an experimental oral drug called NXP800 in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, to find the safest dose and schedule, and then to see if the drug shows promise in specif…

This phase II pilot trial is asking whether combining the chemotherapy drug gemcitabine with the immunotherapy drug nivolumab can shrink tumors in people with advanced small cell lung cancer that has spread and no longer responds to initial treatment. The study enrolls about 14 a…

This early-stage study tests a new drug called GSK3745417, given alone or with another drug (dostarlimab), in about 97 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. This is a…

This trial is testing whether combining two drugs—glumetinib and toripalimab—can help people with advanced non-small cell lung cancer that has not responded to or is no longer controlled by standard treatments. The study is enrolling adults whose cancer has a specific marker (PD-…

This trial offers continued treatment with poziotinib for people with non-small cell lung cancer or breast cancer who have already benefited from the drug in a previous study. The goal is to monitor safety and see how long the cancer remains controlled with extended use. Only pat…

This study tests a three-drug combination (ADI-PEG 20, gemcitabine, and docetaxel) in people with lung cancer that has worsened after initial treatment. The goal is to find the safest dose and see if the combination can shrink tumors or slow disease progression. About 31 particip…

This study tested a new drug called GEN1047 in people with advanced solid tumors (breast, endometrial, ovarian, or lung cancer) who had no other treatment options. The goal was to check safety, side effects, and how the body processes the drug. The study was terminated early, but…

This trial tests whether an experimental drug called XNW5004, which blocks a protein that helps cancer grow, can boost the effects of the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have stopped responding to standard treatments. The study inc…

This trial is testing an experimental drug called NUC-3373, a nucleotide analogue, in combination with standard cancer drugs for people with advanced solid tumors. The study has two parts: one combining NUC-3373 with pembrolizumab, and the other combining it with docetaxel. The g…

This phase 2 trial is testing whether adding an oral chemotherapy drug (CC-486, a form of azacitidine) to the immunotherapy pembrolizumab can help people with advanced non-small cell lung cancer who have already received one round of platinum-based chemotherapy. About 100 partici…

This phase II study tests two staggered schedules of the immunotherapy drug durvalumab combined with standard chemotherapy (pemetrexed and carboplatin) in 43 adults with advanced non-squamous non-small cell lung cancer. The goal is to see if changing the timing of the drugs impro…

This phase II trial tests whether alectinib, a drug typically used for ALK-positive lung cancer, can shrink tumors or control disease in people with advanced non-small cell lung cancer that has a RET gene rearrangement and has progressed after prior treatment. Participants take a…

This early-phase trial is testing a new oral drug called zamzetoclax (GS-9716) in about 145 people with advanced solid tumors. The drug is given alone or combined with standard chemotherapies. The main goals are to find the safest dose and understand side effects. This is a safet…

This early-stage study tests a new drug called ASP4396 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug is given by IV infusion, and the main goals are to check safety, find the right dose, and see how the body handles it. About 175 participa…

This study tested two immunotherapy drugs, ipilimumab and nivolumab, as a first treatment for people with advanced non-small cell lung cancer that had spread. The goal was to see how well the drugs worked and to find markers that predict response. Only 5 people enrolled before th…

This study investigates whether adding the immunotherapy drug durvalumab to stereotactic body radiation therapy (SABR) improves outcomes for people with early-stage non-small cell lung cancer who cannot have surgery. Participants are randomly assigned to receive either SABR alone…

This study tests an experimental drug called ATG-031 in people with advanced solid tumors or B-cell non-Hodgkin lymphomas that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Participants receive ATG-031 by infusion…

This trial tests a new cell therapy called TC-510 for people with advanced cancers that have a protein called mesothelin on their surface, including mesothelioma, ovarian cancer, and pancreatic cancer. TC-510 uses a patient's own immune cells, which are genetically modified to be…

This study tested a daily oral drug called sotorasib in 42 adults with advanced (stage IV) non-small cell lung cancer that has a specific KRAS G12C mutation and has not been treated before. The goal was to see how well the drug shrinks tumors and how safe it is. Participants rece…

This study tested a new drug, GEN1286, in 23 adults with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and see if it could shrink tumors. The trial was stopped early, so results are limited.

This Phase 1 trial tests an experimental drug called OB318 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and to understand how the body processes the drug. Researchers will also look for early signs tha…

This early-stage trial tests a new drug, [177Lu]Lu-EVS459, that delivers radiation directly to cancer cells in people with advanced ovarian or lung cancers. The study aims to see if the treatment is safe and tolerable, and to get an early look at whether it can shrink tumors. Par…

This early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early,…

This early-phase study tested a new drug called BGB-53038, which blocks a family of KRAS proteins that help some cancers grow. It was given alone or with other drugs to 47 people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS mutations. The mai…

This early-stage trial tested an experimental drug called PF-08052666 in 19 people with advanced solid tumors like lung, ovarian, and pancreatic cancers that had not responded to standard treatments. The drug is designed to target and kill cancer cells. The study aimed to find a …

This early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how th…

This trial studies a new drug called SLC-3010, given alone or with chemotherapy (gemcitabine), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. The study is in two par…

This early-stage study tests a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. About 41 participants will ta…

This phase 2 trial tests whether a low dose of radiation (12 Gy in 3 fractions) combined with one dose of the immunotherapy drug durvalumab can boost the immune system's attack on lung cancer cells before surgery. The study enrolls people with stage 2 or 3 non-small cell lung can…

This early-stage study tested a new drug called Debio 0123 in 66 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and to check for side effects and any signs that the drug could shrink tumors. The st…

This study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.

This phase 3 study tested whether adding canakinumab (an anti-inflammatory drug) to standard immunotherapy (pembrolizumab) and chemotherapy could help people with advanced non-small cell lung cancer live longer. The trial enrolled 673 participants but was terminated early, so the…

This was an early-phase study testing a new drug called XMT-2056 in people with advanced solid tumors that have a protein called HER2. The trial aimed to find a safe dose and check for side effects. It was terminated early, so the full results are not available.

This early-stage study tested a new drug called CLN-617, alone or with the immunotherapy Keytruda, in 23 adults with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and find the right dose. However, the trial was terminated, so fu…

This early-stage trial tested a two-step radioimmunotherapy combining GD2-SADA and 177Lu-DOTA in patients with recurrent or metastatic solid tumors, including small cell lung cancer, high-risk neuroblastoma, sarcoma, and melanoma. The goal was to assess safety and find the right …

This study tested a new drug called PRS-344/S095012 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was stopped early, and only 46 people took part.

This study tested a drug called poziotinib in 648 people with advanced non-small cell lung cancer that has specific genetic changes (EGFR or HER2 exon 20 mutations). The goal was to see if the drug could shrink tumors. The study was stopped early, but results showed some patients…

This study tested whether adding tiragolumab to atezolizumab could help prevent lung cancer from returning after surgery and chemotherapy. It included 56 adults with a specific type of lung cancer (PD-L1 positive, stages IIB to IIIB). The trial was terminated early, so results ar…

This early-stage study tested a new drug called VVD-130850, which blocks a protein (STAT3) that helps cancers grow. The trial aimed to find a safe dose and see if the drug works, both alone and with another immunotherapy, in people with advanced solid tumors or blood cancers. The…

This phase 2 trial tested a combination of two drugs—NT-I7 and atezolizumab—in people with advanced non-small cell lung cancer that had not been treated before. The goal was to see if the combo could shrink tumors. However, the study was stopped early and only enrolled 33 out of …

This study tested whether injecting vidutolimod directly into tumors plus giving cemiplimab through a vein could shrink cancers that have spread. The trial included 77 people with several types of advanced cancer. Unfortunately, the study was stopped early, so we have less inform…

This phase 3 trial tests whether adding the chemotherapy drug carboplatin to standard palliative radiotherapy helps control tumor growth and reduce pain better than radiotherapy alone. The study includes adults with advanced lung or head and neck cancer who need palliative radiat…

This early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.

This study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…

This study tested an experimental drug called cofetuzumab pelidotin for people with a specific type of advanced lung cancer (non-small cell lung cancer) that had returned after other treatments. The drug was designed to target a protein called PTK7 found on cancer cells. The stud…

This early-stage study tested a new drug called PF-07284892, alone or with other medicines, in people with advanced solid tumors that had specific genetic changes. The goal was to find the safest dose and check for side effects. The study was stopped early, so results are limited…

This early-phase study aimed to see if adding a special type of radiation therapy to the immunotherapy drug durvalumab could better control stage III lung cancer after standard treatment. Only 6 people took part before the study was stopped. The goal was to check safety and see i…

This study tested a wearable device that sends low-intensity electric fields to tumors, combined with the immunotherapy drug pembrolizumab, in people with advanced non-small cell lung cancer that had already been treated with chemotherapy and immunotherapy. The goal was to see if…

This early-stage trial tested a new drug called 2X-121, alone and combined with another drug called dovitinib, in 14 people with advanced solid tumors. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limited and no c…

This early-phase study tested a new drug called eciskafusp alfa, alone or with another immunotherapy (atezolizumab), in 189 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study…

This early-phase trial tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The study aimed to check safety and see if the drug could shrink tumors. However, the trial was terminated early, so f…

This early-stage trial tested a new gene therapy called quaratusugene ozeplasmid (Reqorsa) combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer who had already received treatment. The goal was to see if the combination was sa…

This study tested a new drug called nogapendekin alfa inbakicept combined with standard treatments for people with advanced or metastatic non-small cell lung cancer. The trial was stopped early, so results are limited. It involved 102 adults who had not received prior chemotherap…

This study aimed to see if combining two drugs, bemcentinib and pacritinib, could help people with advanced lung adenocarcinoma that had stopped responding to other treatments. Only 4 patients were enrolled before the study was terminated early, so no conclusions can be drawn abo…

This pilot study tested giving immunotherapy drugs (durvalumab with or without tremelimumab) along with radiation before surgery for stage III non-small cell lung cancer. Only 9 people took part, and the trial was stopped early. The goal was to see if this combination was safe an…

This early-stage trial tested an experimental drug called BG-60366 in 33 people with advanced EGFR-mutant non-small cell lung cancer. The drug is designed to break down the faulty EGFR protein that drives cancer growth. The study aimed to check safety and find the right dose, but…

This early-stage study tested a new cancer pill (PF-07985045) alone or with other drugs in people with advanced solid tumors that have a KRAS gene mutation. The trial included patients with lung, colon, or pancreatic cancer. The study aimed to check safety and find the right dose…

This early-phase trial tested a new immunotherapy called BI 1821736 in 10 adults with advanced solid tumors that had not responded to standard treatments. BI 1821736 is a specially designed virus meant to kill cancer cells and help the immune system fight the cancer. Participants…

This phase III trial compared two radiation strategies for cancer that had spread to the brain and returned in new spots after initial radiosurgery. One group received focused radiation only to the new tumors, while the other received whole brain radiation that avoided the memory…

This early-phase trial tested a new approach: taking a patient's own white blood cells, genetically modifying them in the lab to recognize a specific cancer mutation (KRAS G12D), and infusing them back to attack tumors. The study enrolled only 5 adults with advanced gastrointesti…

This phase 3 trial compared an experimental drug called tusamitamab ravtansine to the chemotherapy docetaxel in 389 people with advanced non-small cell lung cancer that had a specific marker (CEACAM5). The study aimed to see if the new drug could slow cancer growth or improve sur…

This study tested a personalized treatment using immune cells taken from a patient's own tumor, called tumor-infiltrating lymphocytes (TIL). The cells were grown in a lab and given back to the patient to fight their cancer. The trial included people with advanced melanoma, head a…

This early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…

This early-phase trial tested an oral drug called DT-9081 in 29 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so full results are not available.

This study tested a new combination of two drugs (ociperlimab and tislelizumab) against a standard drug (pembrolizumab) for people with advanced non-small cell lung cancer that had not been treated before. The trial aimed to see if the combo could help patients live longer or slo…

This study tested several immunotherapy-based drug combinations in people with metastatic non-small cell lung cancer. It included two groups: those who had not received prior treatment and those whose cancer had worsened after standard therapy. The trial was terminated early, so …

This study tested whether giving patients their own immune cells (called lymphocytes) after chemotherapy and radiation could help their immune system recover faster. It included 19 adults with lung or esophageal cancer. The treatment was designed to reduce a common side effect of…

This early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after …

This early-stage study tested a new drug called NM6603 in 17 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The trial was ended early, so results are limited.

This early-phase trial tested an experimental drug called Debio 0123 combined with standard chemotherapy (carboplatin and etoposide) in 34 adults with small cell lung cancer that had returned after prior treatment. The main goal was to find a safe dose and check for side effects.…

This study tested whether adding evolocumab (a cholesterol-lowering drug) to standard immunotherapy (nivolumab and ipilimumab) is safe and helps the immune system fight advanced non-small cell lung cancer. It included 19 people with newly diagnosed metastatic lung cancer who had …

This early-stage trial tested a new drug called AXN-2510 in adults with advanced solid tumors that had stopped responding to other treatments. The drug is a special antibody that targets two cancer pathways at once. However, the study was terminated early after enrolling only 3 p…

This phase 2 study tested the drug durvalumab (Imfinzi) combined with two different schedules of stereotactic radiation for people with advanced non-small cell lung cancer. The goal was to see if the combination improved quality of life and controlled tumor growth. However, the t…

This study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head…

This early-phase trial tested the drug plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could shrink…

This study tested a new drug called serabelisib combined with a diet that lowers insulin levels, with or without another chemotherapy drug, in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The goal was to see if the diet could reduce sid…

This early-phase study tested a personalized cell therapy made from a patient's own tumor-fighting immune cells. It aimed to see if the treatment was safe for people with advanced solid tumors that had spread or come back. Only 2 people took part before the study was stopped earl…

This study tested a treatment called GT201, which uses immune cells taken from a patient's own tumor to attack advanced lung cancer. It was designed for adults aged 18-70 with non-small cell or small cell lung cancer that had stopped responding to standard treatments. The study w…

This study tested a new combination of cancer drugs (bemarituzumab plus anlotinib) against a standard treatment (tislelizumab) for people with extensive-stage small cell lung cancer. The goal was to see if the new combo could delay cancer growth or improve survival. However, the …

This early-phase trial tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or returned. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are collected from a tumor, multiplied in a lab, and then inf…

This early-phase trial tested a personalized therapy called GT201, made from a patient's own tumor-fighting immune cells (TILs), for advanced solid tumors. Only 6 people were enrolled before the study was terminated. The treatment involved intensive chemotherapy followed by infus…

This early trial tested a treatment that takes immune cells from a patient's own tumor, grows them in a lab, and gives them back along with an immune-boosting drug called teraplizumab. The goal was to see if this combination is safe and tolerable for people with advanced non-smal…

This study tested a drug called zenocutuzumab combined with other medicines in people with two types of cancer: non-small cell lung cancer with a specific gene change (NRG1 fusion) and advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the…

This early-stage study tested a new drug called NB004 in 25 adults with advanced solid tumors that had no standard treatment options. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limited.

This early-stage study tested an experimental oral drug called M1069 in 15 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so results are limited and…

This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system fight cancer by targeting PD-1 and delivering an immune-boosting protein (IL-18). The …

This phase 2 study tested whether adding itacitinib to standard chemotherapy (docetaxel) could help people with advanced non-small cell lung cancer live longer. The trial was stopped early after enrolling only 9 participants, so we cannot tell if the combination is safe or effect…

This study tested whether matching specific targeted drugs to the genetic changes in a person's ALK-positive lung cancer could improve treatment. It included 10 adults with advanced non-small cell lung cancer that had already been treated. The trial was stopped early due to low e…

This early-stage study tested a new drug called PF-08046037, alone or with another drug (sasanlimab), in 8 people with advanced lung, pancreatic, melanoma, or head & neck cancers. The goal was to check safety and how the body handles the drugs. The trial was terminated early, so …

This early-stage trial tested a personalized treatment called GTE-001, which uses immune cells taken from a patient's own tumor to attack their cancer. It was designed for people with advanced lung adenocarcinoma that had stopped responding to standard chemotherapy. However, the …

This early-phase study tested a combination of two drugs—atezolizumab (an immunotherapy) and epacadostat (an oral drug that helps the immune system attack cancer)—in 29 patients with advanced lung or bladder cancer that had already been treated with chemotherapy. The main goal wa…

This early-stage trial tested an experimental drug called AUR106 in 21 adults with advanced solid tumors (lung, stomach, bladder, kidney, colon, or esophageal cancer) that had come back or spread. The main goals were to check safety, find the right dose, and see how the drug move…

This study looked at giving the immunotherapy drug pembrolizumab (Keytruda) alone or with chemotherapy before surgery for people with early-stage non-small cell lung cancer. The goal was to see if these treatments could shrink tumors and improve outcomes. However, the trial was s…

This early-stage trial tested an oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had not responded to prior treatments. The study aimed to find a safe dose and check how the drug moves through the body. However, the trial was terminated, so resul…

This early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…

This phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…

This early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…

This study tested whether a drug called TNK (tenecteplase) could help drain loculated (pocketed) fluid from the chest in cancer patients better than a saltwater solution. The trial planned to enroll about 20 adults with cancer and a chest tube already in place. However, the study…

This early-phase trial tested whether giving a higher radiation dose directly to the lung tumor (while keeping standard doses to surrounding areas) is safe for people with non-small cell lung cancer. Only 6 participants were enrolled before the study was terminated. The goal was …

This early-stage trial tested an investigational drug called TransCon TLR7/8 agonist, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that could not be cured by surgery or radiation. The study aimed to find a safe dose and check for side effect…

This study tested a new drug called TQB3616 combined with either anlotinib or standard chemotherapy in 21 people with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or slow the cancer's growth. The study was stopped …

This early-phase trial tested a new drug called BAT8007 in 93 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target a protein called Nectin-4 on cancer cells and deliver a chemotherapy agent directly to them. The main…

This early-stage study tested a new drug called DR30303 in 13 people with advanced digestive system cancers that had stopped responding to standard treatments. The drug is a lab-made antibody designed to target a protein called CLDN18.2 found on some cancer cells. The main goals …

This early-phase trial aimed to test the safety of combining two drugs, adagrasib and olaparib, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The study planned to include patients with certain breast, ovarian, pancreatic, and lung canc…

This study tested an experimental RNA-based therapy called BNT142 in people with advanced solid tumors that have a specific protein called CLDN6. The goal was to see if it was safe and could shrink tumors. However, the trial was terminated early, so we don't have clear answers ab…

This early-stage trial tested a new drug called DCC-3116 (inlexisertib) in 91 people with advanced or metastatic solid tumors that have RAS/MAPK pathway mutations. The drug was given alone or combined with other targeted therapies. The study aimed to find safe doses and check for…

This early-stage study tested a new drug combination (MGN1703 plus ipilimumab) in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose of MGN1703 when given with ipilimumab. The study was stopped early, bu…

This study tested whether the drug olaparib could help keep advanced non-small cell lung cancer from growing after initial chemotherapy. Only patients whose cancer responded to platinum-based chemotherapy were eligible. The trial was terminated early, meaning it did not show enou…

This early-phase pilot study looked at combining stereotactic body radiation therapy (SBRT) with surgery for patients with stage I-IIIA non-small cell lung cancer. SBRT delivers very high, precise radiation doses to the tumor while sparing healthy tissue. The study aimed to check…

This study tested a new drug called TRX-221 in people with a specific type of advanced lung cancer (EGFR mutant NSCLC) that had stopped responding to standard treatments. The goal was to see if the drug was safe and could shrink tumors. The trial was stopped early, and only 19 pe…

This early-stage trial tested a new drug, TAS3351, in 18 people with advanced lung cancer that had a specific genetic change (EGFR mutation). The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.

This early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…

This early-stage trial tested an experimental immunotherapy called IMU-201 (PD1-Vaxx) in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or combined with another immunotherapy drug (atezolizumab) and sometimes chemotherapy. The goal was to check …

This early-stage trial tested a combination of two treatments—atezolizumab (an immunotherapy drug) and interleukin-12 gene therapy (which uses a virus to deliver a gene that boosts the immune system)—in 13 people with advanced non-small cell lung cancer that had worsened after in…

This early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…

This early-phase study tested an experimental drug called DS-9606a in 88 people with advanced solid tumors that have a specific protein (Claudin-6). The main goal was to check safety and find the right dose. The trial was terminated, meaning it stopped before completion, so we ha…

This early-phase study tested an experimental drug called BR105 in 31 adults with advanced cancers that no longer responded to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was stopped early, so r…

This early-stage trial tested a new oral drug, AZD0022, designed to block the KRASG12D mutation found in some advanced cancers like lung, pancreatic, and colorectal cancer. The study aimed to see if the drug was safe and tolerable when given alone or with another cancer drug (cet…

This early-stage study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or had no standard treatment options. The main goal was to check the drug's safety and side effects. The trial was terminated early, so its findin…

This study tested a combination of two drugs, bintrafusp alfa and pimasertib, in people whose cancer had spread to the brain. The goal was to find the safest dose and see if the treatment could slow or stop the cancer from growing. The trial was stopped early after enrolling only…

This early-stage trial tested a new immunotherapy drug called vudalimab combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It compared this combination to the standard treatment of pembrolizumab plus chemotherapy. The study was terminated ear…

This early-phase study tested a new drug called GEN2, given with another drug (valganciclovir), in 37 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and check for side effects. The study was terminated, so resul…

This study tested a new experimental drug, BGB-A3055, alone or with another drug (tislelizumab), in people with advanced or metastatic solid tumors. The goal was to check safety, how the body handles the drug, and any early signs of tumor shrinkage. The study was stopped early, b…

This phase 2 trial tested two immunotherapy drugs (tiragolumab and atezolizumab) with or without chemotherapy in 50 people with early-stage non-small cell lung cancer that could be surgically removed. The goal was to see if the treatment shrank tumors before surgery and prevented…

This very early trial aimed to see if adding high-dose vitamin C to the immunotherapy drug durvalumab could boost the immune response against non-small cell lung cancer before surgery. It planned to enroll people with early-stage lung cancer, but was terminated after only one par…

This study tested two immunotherapy drugs, AK119 and AK112, with or without chemotherapy, in 59 people with a specific type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) that had stopped responding to standard targeted pills. The goal was to see if the combination was …

This phase 3 study tested a new drug called pralsetinib against standard chemotherapy for people with a specific type of advanced lung cancer that has a RET gene fusion. The goal was to see if pralsetinib could better delay cancer growth. The trial was terminated early, so full r…

This early-phase study tested a new treatment for adults with advanced solid tumors that had not responded to standard therapies. The treatment combined a cancer-killing virus (onCARlytics) with an immune-boosting drug (blinatumomab), given either into the tumor or through a vein…

This early-stage study tested a new treatment called VAXINIA (CF33-hNIS), a virus designed to attack cancer cells, in 66 adults with advanced solid tumors that had spread. The treatment was given alone or with the immunotherapy drug pembrolizumab, either as a shot into the tumor …

This early-phase trial tested an oral drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and see if tumors shrin…

This study tested a new drug (BMS-986218) plus nivolumab and targeted radiation in people with advanced solid tumors that had spread. The goal was to see if this combination could help the immune system fight cancer better. Only 13 people took part before the study was stopped ea…

This early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the stud…

This early-phase study tested a new drug called BGB-24714, which is designed to help cancer cells die. It was given alone or with chemotherapy to 157 adults with advanced solid tumors that had spread or could not be removed. The main goal was to find a safe dose and see how well …

This phase II trial tested the drug poziotinib in 93 people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes. The goal was to see if the drug could shrink tumors or stop them from growing. The study was terminated early, so results are …

This study tested giving the immunotherapy drug nivolumab along with chemotherapy before surgery for people with early-stage non-small cell lung cancer (stages I to IIIA). The goal was to see if this combination could shrink tumors enough to leave less than 10% cancer cells in th…

This study tested a special grape seed extract (leucoselect phytosome) given before surgery to people with early-stage lung cancer. The goal was to see if it was safe and could slow tumor growth. Only 6 people took part, and the study was stopped early, so we don't have clear ans…

This early-phase study tested a new drug, WBC100, in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see how the drug moves through the body. The trial was terminated, so results…

This early-stage study tested an experimental oral drug (PF-07265028) alone or combined with an immunotherapy injection (sasanlimab) in 21 people with advanced solid tumors, including stomach, lung, and head/neck cancers. The main goals were to find a safe dose and check for side…

This early-stage trial tested a new drug, QEQ278, in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors that have certain gene mutations (KRAS-MAPK pathway). The main goals were to check safety and how the drug moves through the body. The trial w…

This study looked at whether a combination of two drugs, rucaparib and pembrolizumab, could help people with stage IV non-small cell lung cancer keep their cancer from growing after initial treatment. The study included 25 adults whose cancer had not gotten worse after standard c…

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…

This early-stage trial tested a new drug called SIM0501, alone or with another drug (olaparib), in 13 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and how the drug moves through the body. The study was s…

This early-phase study tested a radioactive drug called 225Ac-SSO110 combined with standard immune checkpoint inhibitors for people with advanced small cell lung cancer or Merkel cell carcinoma. The goal was to check safety and find the right dose. However, the trial was terminat…

This early-phase trial tested a combination of two immunotherapy drugs (atezolizumab and varlilumab) plus targeted radiation in 16 people with advanced non-small cell lung cancer that had stopped responding to standard treatment. The goal was to see if the triple therapy was safe…

This early study tested whether combining the immunotherapy drug durvalumab with a special type of radiation called grid therapy could help people with non-small cell lung cancer whose cancer had stopped responding to durvalumab alone. Only 4 patients were enrolled before the stu…

This early-phase trial tested whether a light-activated drug (photodynamic therapy) could help immunotherapy work better in patients with non-small cell lung cancer that has spread to the lining of the lung or with mesothelioma. Only 5 people took part, and the study was stopped …

This early-phase study tested a new drug called PRT3789 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have a SMARCA4 gene mutation. The goal was to see if the combination was safe and could shrink tumors. However, the study was…

This study looked at using a microwave ablation device to destroy lung tumors in people who could not have surgery or chose not to. It included 13 adults with non-small cell lung cancer or tumors that had spread to the lung. The treatment was given through a needle inserted into …

This phase II trial tested whether the immunotherapy drug toripalimab could help patients with limited-stage small cell lung cancer stay cancer-free longer after standard chemoradiotherapy. The study planned to enroll 170 adults aged 18-75 who had not progressed after treatment. …

This early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated…

This study tested a new drug combination (SON-1010 plus atezolizumab) in people with advanced solid tumors, especially platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow tumor growth. The trial was terminated early, so results are li…

This early-phase trial tested an experimental drug called GEN1078 in 3 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check for side effects and see how the body processes the drug. The trial was terminated early, so r…

This early study tested a new drug called PHN-010 in 26 people with advanced cancers like lung, colon, and ovarian cancer. The drug is designed to deliver a powerful treatment directly to cancer cells. The main goals were to check safety and find the right dose, but the study was…

This early-phase trial tested the safety and dosing of a new drug called modakafusp alfa, given alone or with pembrolizumab, in adults with advanced solid tumors or melanoma. The study aimed to find the highest safe dose and check for side effects. It was terminated early, so res…

This study looked at whether adding radiation to the chest could improve survival for people with extensive-stage small-cell lung cancer who were already receiving chemotherapy and immunotherapy. The trial planned to enroll 239 participants but was terminated early. The main goal…

This early-phase trial tested the combination of the immunotherapy drug pembrolizumab (Keytruda) with precise, high-dose radiation (SBRT) in patients with advanced non-small cell lung cancer that had progressed after chemotherapy. The study aimed to find the safest radiation dose…

This early-phase trial tested a new treatment called HV-101 for people with advanced solid tumors that had spread or come back. The therapy uses a patient's own immune cells (TILs) taken from their tumor, grown in a lab, and then given back along with chemotherapy and IL-2. The s…

This early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…

This early-phase trial tested two immunotherapy drugs, ipilimumab and nivolumab, in people with HIV who had advanced solid tumors or Hodgkin lymphoma that had spread or come back. The goal was to find the safest dose and see if the combination could shrink tumors. The study was t…

This early-phase trial tested a personalized cancer treatment called tumor-infiltrating lymphocyte (TIL) therapy. Doctors took immune cells from each patient's own tumor, grew them in a lab, and infused them back to fight the cancer. The study enrolled only 5 adults with advanced…

This trial tested two immune-boosting drugs, tiragolumab and atezolizumab, with or without chemotherapy, in people with non-small cell lung cancer that had spread to the brain. The goal was to see if the combination could control the brain tumors and delay the need for radiation.…

This early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…

This study tested a new drug called SAR444200, alone or with other cancer treatments, in 33 adults with advanced solid tumors that had spread and were not responding to standard therapy. The main goals were to check safety and find the right dose. The trial was terminated early, …

This early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…

This early-phase study aimed to see if combining two immune-stimulating drugs (rintatolimod and interferon alpha-2b) could help cancer patients fight off COVID-19. Only 4 people took part before the study was stopped early. The main goals were to check safety and measure how the …

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in people with advanced non-small cell lung cancer that had spread. The goal was to see if these drugs could control the cancer without needing chemotherapy. Only 5 people took part before the study was stopped …

This early-stage trial tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors including colorectal, nasopharyngeal, and lung cancers. The goal was to find a safe dose and see if the combination could control the disease. However, the …

This study tested a new drug, felmetatug vedotin, alone or with pembrolizumab, in people with advanced solid tumors like ovarian, breast, and lung cancer. The goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This early-phase trial tested the immunotherapy drug sasanlimab combined with various targeted therapies in 34 people with advanced non-small cell lung cancer. The goal was to check safety and find the right doses. However, the study was terminated early, meaning we have limited …

This early-phase trial tested a new treatment called C-TIL051 for people with advanced non-small cell lung cancer that no longer responded to standard immunotherapy. The treatment involved taking immune cells from the patient's tumor, growing them in a lab, and infusing them back…

This early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…

This early-phase trial tested two experimental drugs, tuvusertib and PLX038, in 10 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find a safe dose and see if the combination could shrink tumors. However, the study was terminated e…

This early-phase trial tested an experimental drug called IBI3004 in people with advanced solid tumors that could not be removed by surgery. The study aimed to find a safe dose and check for side effects, but it was terminated after enrolling only 5 participants. Because it stopp…

This early-stage study tested a new drug called RO7759065, alone or with another drug (atezolizumab), in 12 people with advanced solid tumors that could not be cured. The main goals were to check safety and how the drug moves through the body. The study was stopped early, so resu…

This study tested a combination of two drugs, HBI-8000 and pembrolizumab (Keytruda), in people with advanced non-small cell lung cancer. The goal was to see if the combination was safe and could shrink tumors. However, the trial was stopped early after enrolling only 5 participan…

This study tested a new pill (SLC-391) combined with an immunotherapy drug (pembrolizumab) in 36 adults with advanced non-small cell lung cancer that had spread. The goal was to find a safe dose and see if the combination could shrink tumors. The trial was terminated early, so re…

This early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the…

This early-stage trial tested a new drug called M9466 combined with standard chemotherapy in people with advanced solid tumors or colorectal cancer who had no other treatment options. Only 3 people took part before the study was stopped. The main goal was to check safety and find…

This early-stage trial tested a new drug called MYTX-011 for people with advanced non-small cell lung cancer (NSCLC) that had spread or come back after standard treatments. The drug is an antibody-drug conjugate designed to deliver a powerful chemotherapy directly to cancer cells…

This study tested a combination of two targeted drugs, tarloxotinib and sotorasib, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants had already tried other treatments, including a KRAS-targeting drug, and their c…

This study tested whether adding the immunotherapy drug durvalumab to standard chemotherapy could shrink large stage III lung tumors enough to allow patients to then receive radiation therapy. The trial was stopped early after enrolling only 10 people, so results are limited. The…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise, high-dose radiation (SBRT) could help prevent early-stage non-small cell lung cancer from returning. The study enrolled 448 people with stage I or II lung cancer who could not hav…

This early-stage trial tested a new drug called RP-6306 combined with standard chemotherapy (FOLFIRI) in 38 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumor…

This early-phase study tested an oral drug called Debio 0123 combined with the chemotherapy carboplatin in 76 people with advanced solid tumors that had stopped responding to prior platinum-based treatments. The main goals were to find a safe dose and check for side effects. The …

This early-phase study tested a new oral drug (RP-6306) combined with the chemotherapy gemcitabine in 67 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety, find the best dose, and see if the combination could sh…

This early-stage study tested a new drug (JS004) combined with another immunotherapy (Toripalimab) in 31 people with advanced solid tumors like liver, esophageal, stomach, cervical, or colorectal cancer. The goal was to check safety and see if the combination could help control t…

This study tested a new drug called BAT3306 against the standard treatment Keytruda, both combined with chemotherapy, in 162 people with advanced non-small cell lung cancer. The goal was to see if BAT3306 works as well as Keytruda in shrinking tumors. The trial was stopped early,…

This study tested a new drug called TAK-186 in 95 adults with advanced or metastatic cancers of the head and neck, lung, or colon that could not be removed by surgery. The main goal was to check for side effects and find the best dose. The study was stopped early, so results are …

This trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …

This early-phase trial tested a new drug called BLU-222, alone or with other medicines, in about 50 people with advanced solid tumors (including certain breast, ovarian, and stomach cancers). The goal was to find a safe dose and see if it shrinks tumors. However, the study was te…

This early-phase trial tested an oral drug called RP-1664 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study was terminated early, so full results may not be availa…

This early-phase study tested a new drug called BRY805 in 13 people with advanced solid tumors who had run out of standard treatment options. The main goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This early-phase trial tested a new treatment called BT-001, a virus designed to infect and kill cancer cells, given alone or with the immunotherapy drug pembrolizumab. The study involved 31 people with advanced solid tumors like melanoma, lung cancer, or sarcoma that had spread.…

This study tested whether adding bintrafusp alfa (an immunotherapy) to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer who have already tried other treatments. Only 10 people took part before the study was stopped early. The goal was to see…

This study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…

This study looked at whether adding a single dose of radiation to the immunotherapy drug atezolizumab could help people with advanced lung cancer whose disease had gotten worse after both chemotherapy and another type of immunotherapy. The trial planned to include 12 adults with …

This early-stage trial tested a new drug called FAZ053, alone or with another drug (PDR001), in 154 adults with advanced solid tumors. The goal was to check safety and find the right dose by boosting the immune system to attack cancer. The study was terminated early, so full resu…

This study tested an experimental drug called SQ3370 in 53 people with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and find the best dose, as well as see if it could shrink tumors. The study was terminated earl…

This study tested a new way to deliver radiation therapy for central lung tumors using MRI guidance. The goal was to see if it is safe and can control tumors better than standard CT-guided radiation. Only 3 people took part before the study was stopped early.

This study tested an experimental drug called VLS-101 in 102 people with advanced solid tumors, including breast, lung, ovarian, stomach, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the t…

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…

This study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The drug was taken by mouth and aimed to shrink tumors by blocking a protein involved in cancer cell growth. The trial was terminated early, …

This early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …

This phase 2 study tested the drug pemigatinib in 111 people with advanced solid tumors that have specific FGFR gene mutations or translocations. The goal was to see if the drug could shrink tumors. The trial was terminated early, so the full results are not available.

This study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.

This study tested whether adding the drug vorolanib to standard maintenance therapy with atezolizumab could help people with extensive-stage small cell lung cancer stay cancer-free longer after initial chemotherapy. Only 11 participants were enrolled before the study was terminat…

This early-phase study tested the safety of an oral drug called LY3405105 in 54 people with advanced solid tumors. The trial was divided into two parts to find the right dose and to see if the drug could shrink tumors. However, the study was terminated early, meaning the drug did…

This study tested an experimental drug called REGN5093-M114, alone or with another drug, in people with advanced non-small cell lung cancer that has too much MET protein. The goal was to find a safe dose and see if it could shrink tumors. The study was stopped early, but the resu…

This study looked at whether adding the drug pembrolizumab to chemotherapy could help people with a type of lung cancer that has spread to the brain but isn't causing symptoms. The goal was to control the cancer in the brain and body while keeping quality of life. Only 3 people t…

This early-phase trial tested a new drug, RP-3500 (camonsertib), combined with existing PARP inhibitors (niraparib or olaparib) in 156 adults with advanced solid tumors that have specific genetic markers. The goal was to find safe doses and see if the combination could shrink tum…

This early-phase study tested an experimental drug called ABBV-303, alone or with another drug (budigalimab), in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was termin…

This study tested a new drug (tusamitamab ravtansine) combined with pembrolizumab and chemotherapy in 57 people with advanced non-squamous non-small-cell lung cancer that has a specific marker (CEACAM5). The goal was to see if the combination was safe and shrank tumors. The trial…

This early-stage trial tested a new drug called bemcentinib added to standard chemotherapy and immunotherapy for people with advanced non-squamous lung cancer. The study aimed to check safety and find the right dose, but it was terminated early. Only 26 people took part, so we ca…

This study tested an experimental drug called telisotuzumab vedotin for people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a MET gene change. The goal was to see if the drug could shrink tumors. The trial was stopped early and e…

This early-phase trial tested a new drug called INCB062079 in 25 people with advanced liver cancer and other solid tumors. The main goal was to check safety and find the best dose. The study was terminated early, so results are limited.

This study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in 70 people with advanced solid tumors, including lung and colorectal cancers. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated …

This early-stage trial tested an experimental drug called LY3127804, alone or combined with another cancer drug (ramucirumab), in 62 people with advanced solid tumors. The main goal was to find a safe dose. The study was terminated early, and researchers could not determine a max…

This early-phase study tested a new drug called ZW171 in 32 people with advanced ovarian, lung, or other cancers that have a protein called mesothelin. The main goals were to check the drug's safety and find the right dose. The study was terminated early, so results are limited.

This early-phase study tested a new drug called PF-07284890, alone or with another drug (binimetinib), in 65 people with advanced cancers that have a specific genetic change (BRAF V600 mutation), including cancers that spread to the brain. The trial was terminated early, but rese…

This study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…

This study tested a new treatment for people with non-small cell lung cancer or kidney cancer that had spread to up to six spots in the body. The treatment combined a special type of radiation therapy (PULSAR) with immunotherapy drugs (pembrolizumab or nivolumab), with or without…

This early-stage study tested a new drug called ZL-1218, alone or with another cancer drug, in 34 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, side effects, and how the drug moves through the body. The …

This early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…

This early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.

This study tested the drug capmatinib in people with early-stage non-small cell lung cancer that has a specific genetic change (MET mutation). The goal was to see if taking the drug before and after surgery could improve outcomes. However, the trial was stopped early after enroll…

This phase 2 study tested a combination of the targeted drug osimertinib (Tagrisso) plus standard chemotherapy as a first treatment for advanced non-small cell lung cancer with uncommon EGFR mutations. Only 4 participants were enrolled before the study was terminated, so no meani…

This early-stage trial tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had specific genetic changes (EGFR or HER2). The goal was to find a safe dose and see if the drug could shrink tumors. The study was stopped e…

This early-stage study tested a new drug called AMG 794 in adults with advanced lung, ovarian, or other solid tumors that have a specific protein (claudin 6). The main goals were to check safety and find the right dose. However, the study was stopped early after only 3 people enr…

This phase 2 trial tested the drug futibatinib in 115 people with advanced solid tumors or blood cancers that have specific FGFR gene changes. The goal was to see if the drug could shrink tumors or cause remission. The study was terminated early, so final results are not yet clea…

This phase 2 trial tested a new drug called THOR-707 (Pegenzileukin) combined with other cancer treatments, including pembrolizumab, in 106 people with advanced lung cancer or pleural mesothelioma. The goal was to see if the combination could shrink tumors. However, the study was…

This phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …

This early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…

This early-phase trial tested an experimental drug called WJ05129, taken as a tablet, together with the chemotherapy drug paclitaxel in people with advanced solid tumors that had spread. The study aimed to find safe doses and check for side effects. Only 26 people were enrolled, …

This early-phase study tested the drug INCB086550 in 3 Japanese patients with advanced solid tumors that had stopped responding to other treatments. The main goal was to check safety and find the right dose. The study was terminated early, so we have limited information on how we…

This early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study w…

This study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.

This phase 3 trial tested a combination of three drugs—camrelizumab (an immunotherapy), famitinib (a targeted therapy), and standard chemotherapy—in 48 people with advanced non-squamous non-small-cell lung cancer that did not have certain genetic changes. The study aimed to see i…

This early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…

This early-phase trial tested a new drug called BGB-30813, either alone or combined with the immunotherapy tislelizumab, in 44 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety, find the right dose, and see if the…

This early-phase trial tested a drug called RiMO-401, injected directly into tumors and followed by radiation, in people with advanced cancers that had not responded to standard treatments. Only 5 patients were enrolled before the study was terminated. The main goal was to find a…

This early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…

This early-phase study tested an experimental drug called KD033 (SAR445710) in 45 adults with advanced or metastatic solid tumors. The main goal was to check safety and find the right dose, while also looking for any anti-cancer effects. The trial was terminated, so final results…

This early-phase study tested an experimental drug called BMS-986258, alone or combined with the immunotherapy nivolumab (Opdivo), in 92 people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and find the right dose. However, the …

This early-stage trial tested an experimental drug called SAR443216 in 44 adults with advanced HER2-expressing solid tumors (such as breast, lung, or gastric cancer) that had come back or stopped responding to standard treatments. The study aimed to find a safe dose and check for…

This early-stage trial tested a new drug called BDC-1001, alone or with the immunotherapy nivolumab, in 175 people with advanced HER2-positive cancers (like breast, colorectal, and stomach cancers) that had stopped responding to other treatments. The study aimed to check safety a…

This early-phase trial tested the safety of giving a precise form of radiation (SABR) either before or after the immunotherapy drug pembrolizumab in 13 people with metastatic non-small cell lung cancer. The goal was to see if the combination caused severe side effects and whether…

This phase 2 trial tested a personalized cancer vaccine called TLPO in 63 people with various solid tumors. The vaccine was made from a patient's own tumor material to train their immune system to fight the cancer. The study aimed to see if the vaccine could delay disease progres…

This early-phase trial tested a new drug called LB4330 in people with advanced solid tumors that had stopped responding to standard treatments. LB4330 is designed to help the immune system attack cancer cells. The study aimed to find a safe dose and check for side effects, but it…

This early-stage trial tested an experimental drug called SAR441000, injected directly into tumors, either alone or with another drug (cemiplimab) given through a vein. The study aimed to find a safe dose and see if the combination could shrink tumors in people with advanced soli…

This study tested whether a smartphone app (Craving-to-Quit) or group mindfulness sessions work better for helping cancer survivors stop smoking. Participants also used nicotine patches. The trial was terminated early and only enrolled 20 people, so the results are not conclusive…

This study tested a new drug called WJ13405 in 14 people with advanced non-small cell lung cancer that had stopped responding to other treatments. The goal was to check safety, side effects, and how well the drug worked. However, the trial was terminated early, so results are lim…

This early-phase trial tested an experimental antibody called hSTC810 combined with the chemotherapy drug paclitaxel in 10 adults with relapsed or refractory extensive-stage small cell lung cancer. The goal was to see if the combination is safe and helps shrink tumors or slow the…

This study tested an experimental drug called MORAb-202 in 31 people with a type of advanced lung cancer (non-small cell lung cancer adenocarcinoma) that had gotten worse after other treatments. The drug is designed to target and kill cancer cells while sparing healthy ones. The …

This early-phase trial tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in people with advanced solid tumors such as head and neck or gastrointestinal cancers. The study aimed to find safe doses and check for early signs of effectiveness. It …

Researchers are testing a breathing sensor called SPI that synchronizes PET/CT scans with a patient's breath. The goal is to see if this device can produce clearer images of lung tumors and nodules. Each participant undergoes a scan with both the SPI device and a standard breathi…

This early-stage trial tests a radioactive imaging agent called [111In]-FPI-2107 in 12 Chinese adults with EGFR-mutant non-small cell lung cancer. The goal is to see if it is safe and can help detect tumors on SPECT scans. Participants receive the agent plus an unlabelled antibod…

This pilot study asks whether a blood marker called procalcitonin can help predict bacteremia—a serious bacterial infection in the blood—in children with cancer who develop a fever. Currently, doctors rely on blood cultures, which can take up to 48 hours or give false negatives. …

This early-phase trial tested a radioactive imaging agent called 68GaNOTA-Anti-MMR-VHH2 to see if it could safely highlight tumors on PET scans. It involved 13 adults with advanced solid tumors, breast cancer, or melanoma. The study was terminated early, so we have limited inform…

This study looked at whether analyzing sputum (phlegm) with automated cytometry, combined with low-dose CT scans and blood tests, could better detect lung cancer in workers heavily exposed to asbestos. The goal was to reduce false positives and improve early diagnosis. The trial …

This pilot study tested whether a special PET scan (FDG-PET/CT) can detect hidden heart inflammation in cancer patients receiving immune checkpoint inhibitors (ICIs). The goal was to catch this inflammation early, before it becomes severe. Only 2 participants were enrolled, and t…

This study tested whether adding a special laser imaging technique (nCLE) and a dye (fluorescein) to a standard needle biopsy could help doctors diagnose lung cancer more accurately. The plan was to compare the combined approach to the standard biopsy alone in people with suspici…

This study looked at whether a blood test (called a fluid biopsy) could help diagnose lung cancer. Researchers collected blood samples from 51 people who were either scheduled for a lung biopsy or had recently had one. The goal was to see if the blood test could accurately detect…

This study compared two standard drugs—olanzapine and dexamethasone—for preventing nausea and vomiting caused by chemotherapy. Researchers wanted to see if olanzapine could work as well as the steroid dexamethasone, potentially allowing patients to avoid steroid side effects. The…

This study tests whether a special low-calorie, plant-based diet that mimics fasting can reduce common side effects like rash, diarrhea, and fatigue in cancer patients receiving immunotherapy. Ten adults with advanced cancer will follow the diet and report their symptoms. The goa…

This study tests a program where older adults with advanced cancer and their caregivers talk about their lives together. The goal is to see if this approach is practical and helps improve emotional well-being and relationship quality. About 60 patient-caregiver pairs will be rand…

This study tested whether monitoring daily step counts in people with stage III non-small cell lung cancer during chemoradiotherapy helps doctors provide better supportive care and reduce hospital stays or treatment delays. Only 3 participants were enrolled before the study was s…

This study looked at whether a supervised exercise program is possible for people with advanced bronchial cancer or mesothelioma. The goal was to see if patients could complete at least 6 rehab sessions to help with weakness and poor quality of life caused by the disease and its …

This study tested a mobile app called Apricity CARE to help ethnic and racial minority patients with non-small cell lung cancer report side effects from immunotherapy. The goal was to reduce treatment delays and hospital visits. The study was stopped early, but it aimed to improv…

This study looked at whether a program combining different types of exercise could help people with advanced lung cancer feel less tired, move better, and have a better quality of life. It was designed for adults with stage III or metastatic non-small cell lung cancer who were al…

This study tested whether a digital platform could improve collaborative care for depression in cancer patients. About 300 adults receiving cancer treatment with significant depression symptoms were enrolled. The platform aimed to help care managers track symptoms and coordinate …

This study tested a text-message-based diet program called Txt4fasting for people with breast or lung cancer that spread to the brain. The goal was to see if eating only during certain hours could reduce thinking and memory problems after radiation. Only 1 person enrolled before …

This study tested whether a 12-week program of walking and resistance exercises or nutrition education could reduce nerve pain caused by platinum chemotherapy. The trial enrolled 36 adults with cancer who were receiving oxaliplatin or cisplatin. The study was terminated early, so…

This early-phase trial tested whether a special MRI scan using hyperpolarized xenon gas could help doctors plan radiation therapy for non-small cell lung cancer. The goal was to map which parts of the lung are working well so radiation can avoid them, potentially reducing side ef…

This study tested two educational programs for parents with late-stage cancer who have children aged 5 to 17. The programs were designed to improve parent-child relationships and boost parents' confidence in talking about cancer with their kids. Researchers hoped to reduce anxiet…

This study was designed to track side effects and quality of life in people aged 70 and older with advanced melanoma or non-small cell lung cancer who are starting immunotherapy. Researchers planned to monitor 40 participants for serious side effects and changes in daily well-bei…

This study tested whether a digital health app (Roche DPM Module) helps cancer patients manage symptoms and reduce healthcare visits while on systemic treatment. About 49 participants used the app alongside standard care. The trial was terminated early, so results are limited.

This study tested an online support group for young adults (ages 18-39) who had cancer treatment and were feeling anxious or distressed during the COVID-19 pandemic. The goal was to see if teaching healthy coping skills through a virtual group could improve their mood and confide…

This study tested whether providing palliative care at home, through a team of doctors, nurses, social workers, and chaplains, could improve symptoms and quality of life for people with advanced cancer, heart failure, or COPD. The plan was to enroll over 1,100 patients, but the t…

This small, early-stage trial tested a drug called imsidolimab for treating acne-like skin rashes that can occur in cancer patients taking certain targeted therapies. Only 4 people were enrolled before the study was stopped. Because of the very small size and early termination, w…

Researchers at Pennington Biomedical Research Center are studying how unintended weight loss affects the way the body burns fuel in people with advanced non-small-cell lung cancer. Participants eat a liquid mixed meal while researchers measure their breathing to see whether their…

This study is testing whether special lab tools—like analyzing tiny particles from blood cells or growing mini-tumors in a dish—can predict how well immunotherapy drugs work in people whose lung cancer has returned. About 40 participants will receive standard immunotherapy drugs …

This early-phase study by AstraZeneca examines how the experimental drug ceralasertib is absorbed, distributed, and eliminated in people with advanced solid tumors. Participants receive the drug orally and a tiny radiolabeled intravenous dose to track its journey. Researchers mea…

This study aims to develop a smoking cessation program specifically designed for homeless youth. Researchers will interview and survey participants to understand their motivations for smoking and quitting. The goal is to build a program that addresses the unique challenges these …

This pilot study aimed to see if combining PET and MRI scans could better show tumor differences in non-small cell lung cancer (NSCLC). Only 11 people were enrolled before the study was stopped early. The goal was to check if the imaging method was consistent when used by differe…

This study is looking at whether tumor biopsies can help predict which patients with melanoma, non-small cell lung cancer, or head and neck cancer will respond to immunotherapy drugs called PD-1 or PD-L1 inhibitors. Researchers will collect tissue samples from about 152 adults be…

This early-stage study aimed to see how the experimental drug ceralasertib affects the way the body processes three other drugs (Drug X, Y, and Z) in people with advanced solid tumours. Only one person was enrolled before the study was terminated, so no useful information was gat…

This study is measuring how often a specific genetic marker (HLA-A*02:01) and a cancer-related protein (NY-ESO-1) appear in Taiwanese patients with solid tumors like head and neck, liver, lung, breast, and esophageal cancers. By understanding these frequencies, researchers hope t…

This study tested an electronic platform called eGAP that helps older cancer patients (65+) complete questionnaires about their health. The goal was to see if the platform was easy to use and practical for patients, caregivers, and doctors. The study was terminated early after en…

This study aimed to see if COVID-19 vaccines cause more side effects in cancer patients receiving immunotherapy. Researchers planned to track 125 patients from several hospitals in France, recording any local or systemic side effects. The study was terminated early, so the full r…

This study looked at why minority cancer patients often don't take part in clinical trials. Researchers surveyed patients about their understanding and attitudes, then tested an educational video and booklet to see if it boosted enrollment. The goal was to create a personalized p…

This study tested whether a visual consent form with pictures helps patients with cancer or Alzheimer's understand research better than standard text. Researchers planned to enroll 266 adults across three U.S. sites. The trial was terminated early, so results may be limited.

This early-stage study tested whether inhaling the cancer drug afatinib works as well as taking it by mouth. Four healthy adult smokers received both forms in separate sessions to compare drug levels in the blood and lungs. The study was terminated early, so the findings are limi…

This early-phase study tested whether two optical imaging agents could be used during a bronchoscopy to visualize activated neutrophils and a cancer-related protein called c-MET in lung tumors. Five participants with lung cancer received the agents through a special catheter whil…

This study tested whether consumer movement trackers could provide a more precise measure of cancer patients' physical abilities than the standard ECOG score, which relies on a doctor's observation. Researchers enrolled 41 cancer patients and used a Kinect device to record their …

This study looked at how cancer patients experience being rotated horizontally in the Nano-X system. 43 patients completed questionnaires about anxiety and motion sickness before and after rotation. The study was terminated early, so findings are limited.

This study aimed to help low-income pregnant women stop smoking and make their homes smoke-free. Smoking during pregnancy raises the risk of cancer and can lead to low birth weight and other health problems for the baby. The program offered support and referrals to services durin…

This study aimed to see if immune cells in the blood match those inside lung tumors. Researchers hoped to find a simple blood test that could help doctors decide which patients might respond to immunotherapy. The study planned to enroll 22 people with early-stage lung cancer who …

This study aimed to collect tumor tissue from patients with lung, chest cavity, ovarian, or bladder cancers, or those who had adoptive cell therapy, within three hours after death. Participants received inpatient hospice care at the NIH Clinical Center. The goal was to analyze th…

This study followed 83 people with advanced non-small cell lung cancer who were starting standard treatments. The goal was to collect information to help develop a digital tool that can spot early signs of pneumonitis/ILD, a serious lung inflammation that can occur as a side effe…

This study aimed to screen cancer patients for genetic markers before they joined other clinical trials, hoping to save time and improve drug dosing. Only 8 adults were enrolled before the study was terminated early. The approach was meant to help match patients to the right tria…

This study explored whether a wearable brain scanner (fNIRS) could objectively measure pain in cancer patients and survivors. It also tested if virtual reality (VR) relaxation could help reduce pain. The study included 106 participants, including healthy volunteers and cancer pat…

This study looked at how the cancer drug tazemetostat is processed in the body of people with advanced solid tumors who also have moderate or severe liver impairment. Researchers compared drug levels in these patients to those with normal liver function. The trial was terminated …

This pilot study aimed to understand how brown adipose tissue (brown fat) might contribute to weight loss in cancer patients. Researchers planned to measure energy use in patients with and without active brown fat. However, the study was terminated early and only enrolled 3 parti…

This pilot study tested whether a new PET imaging tracer called [18F]F-AraG could track immune T cells inside tumors of patients with advanced solid cancers who were receiving immunotherapy. Nine patients were enrolled to have PET scans and tumor biopsies before and after treatme…

This study looked at whether a blood test (liquid biopsy) could find EGFR gene mutations in lung cancer patients as accurately as a standard tumor biopsy. Researchers planned to enroll 21 patients with advanced lung cancer who had not yet received treatment. The study was termina…

This study looked at how long to continue immunotherapy in people with advanced non-small cell lung cancer who had already responded well to treatment for 6 to 12 months. The goal was to see if stopping or continuing treatment made a difference in keeping the cancer from growing.…

This study used PET scans to track where a new antibody drug (S095012) goes in the body and in tumors of people with advanced solid cancers. Only 3 participants were enrolled before the study was stopped early. The goal was to understand how the drug spreads and targets tumors, n…

This study aimed to see if a culturally tailored educational video could help African American, Korean, and Chinese adults learn about lung cancer and screening. Researchers planned focus groups and interviews with 11 participants to understand barriers. The trial was terminated …

This early-phase study tested whether a special MRI technique could detect early signs of heart damage caused by radiation therapy in people with thoracic or left-sided breast cancer. The approach used an injected substance (hyperpolarized pyruvate) to measure changes in heart ce…

This pilot study tested a program called SHAREDCare, where a navigator helps lung cancer survivors identify their needs and create a plan to address them. The goal was to improve follow-up care after cancer treatment. However, the study was terminated early and included only 5 pe…

This observational study looked at how much of the immunotherapy drug pembrolizumab stays in the blood of patients with advanced non-small cell lung cancer. Researchers measured drug levels and immune responses in 80 patients receiving pembrolizumab alone or with chemotherapy. Th…

This early-phase study aimed to use PET imaging to track how a new drug (BI 754111) spreads in the body and reaches tumors in people with advanced non-small cell lung cancer or head and neck cancer. Only 8 participants were planned, and the study was terminated early. The main go…

This study collected fluid from the abdomen or lungs, plus blood, from 22 adults with solid tumors. The goal was to learn more about cancer biology, not to provide a direct treatment. Researchers hope these samples will help them understand how cancer grows and lead to better the…

This study aimed to understand how COVID-19 affects people with cancer, especially those receiving treatment. Researchers planned to measure how many cancer patients had COVID-19 without symptoms and how their immune systems responded. The study was terminated early, so results a…

This study looked at the genetics of people with multiple lung tumors (multifocal lung adenocarcinoma). Researchers collected tissue and blood samples from 100 participants during surgery to analyze their DNA. The goal was to see if genetic information could help guide treatment …

This study aimed to find genetic changes in lung tissue and blood that could predict how squamous cell lung cancer progresses. Researchers planned to collect samples from 200 patients undergoing lung procedures, but the study was stopped early with only 22 participants. No treatm…

This study looked at how adults with advanced or metastatic solid tumors absorb, break down, and remove the drug subasumstat. Only 3 people took part, and the study was stopped early. The goal was to measure the drug in urine and stool, not to test if it works as a treatment.

This study tested a new 3D scanner to measure how the brain shifts during surgery for epilepsy or tumor removal. Only one person took part before the study was stopped. The goal was to see if the scanner could accurately track brain surface changes over time, which could help sur…

This study tested whether wearable fitness trackers (like Fitbits) and smartphone diaries can give a more accurate picture of cancer patients' physical function than standard doctor assessments. Researchers enrolled 31 cancer patients starting early-phase clinical trials. The goa…